1. Pharmacological Treatment of Tachyarrhythmias in Acute Myocardial Infarction - a Review
- Author
-
Maria Dorobantu, Alexandru Deaconu, Andrei Dan Radu, and Silvia Deaconu
- Subjects
medicine.medical_specialty ,business.industry ,ventricular arrhythmias ,acute myocardial infarction ,medicine.disease ,atrial fibrilation ,RC31-1245 ,Pharmacological treatment ,antiarrhythmic drugs ,Internal medicine ,medicine ,Cardiology ,cardiovascular system ,Myocardial infarction ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,business ,health care economics and organizations - Abstract
Acute myocardial infarction (AMI) causes severe metabolic and electrophysiological changes that induce silent or symptomatic life-threatening arrhythmias. Ventricular arrhythmias and atrial fibrillation are common during the early phase of AMI and are also important prognostic factors. Rapid identification and treatment of these arrhythmias can be life-saving, since in-hospital mortality rises dramatically in patients who develop arrhythmias with a fast ventricular rate following an AMI. Along with myocardial revascularization, adequate pharmacological therapy of hemodynamically relevant arrhythmias is generally useful. Since there are no controlled randomized trials comparing different antiarrhythmic drugs (AADs) in AMI, optimal decision making is based on medical societies guidelines recommendations and clinical judgement.
- Published
- 2021